Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Phase II, randomized, safety and efficacy study in recurrent/metastatic breast cancer with
accessible lesions.
Primary End point is rate of Progression Free Survival (PFS) at the 16 week treatment time
point. Hypothesis: Adenoviral vector (Ad-RTS-hIL-12) alone and in combination with
chemotherapy (palifosfamide) is safe and efficacious.